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Ethylene glycol monoalkyl ethers (EGMEs),
such as 2-butoxyethanol (BE), are a major class of
industrial chemicals extensively used in the manu-
facture of a wide range of industrial and domestic
products (1).
These chemicals are readily absorbed to the
organism following inhalation, oral, and dermal
exposure (2-4). EGMEs are metabolized primarily
via alcohol (ADH) and aldehyde (ALDH) dehydro-
genases with the formation of appropriate alkoxyac-
etaldehydes and alkoxyacetic acids (3, 5). In addi-
tion, parent compounds are partially conjugated
with both glucuronic and sulfuric acids. These latter
metabolic pathways are alternative for oxidation of
this chemicals (3).
EGMEs cause a wide range of toxic effects in
humans and laboratory animals including reproduc-
tive and developmental toxicity, as well as hemato-
toxicity and nephrotoxicity. Alkoxyacetic acids are
considered to be the proximate toxic metabolites.
Poisoning with EGMEs cause clearly marked meta-
bolic acidosis and intravascular hemolysis as a pri-
mary effects (6-9) and renal failure as a secondary
effect (10).
Methanol and ethylene glycol poisonings are
generally treated with the combination of ethanol as
antidote, and hemodialysis. Fomepizole (4-methyl-
pyrazole, MP), a competitive inhibitor of ADH, has
more recently been used for the treatment of
methanol and ethylene glycol intoxications due to its
capability of blocking the toxic metabolism of these
chemicals (11, 12). Also, MP is used in cases of
severe disulfiram-ethanol reactions. The signs of
these reactions are tachycardia, hypotensia and ECG
disturbances of repolarization and also myocardia
ischemia as a complication (13). There are few data
indicating that MP may be powerful for the treat-
ment of EGMEs poisoning (14, 15 ).
The current investigation was undertaken to
compare the efficiency of both pyrazole (PY) and
MP in male rats acutely intoxicated with BE. The
intravascular hemolysis induced by BE as a critical
effect was taken under consideration. 
EXPERIMENTAL
Chemicals
BE, PY, and MP were purchased from Sigma-
Aldrich Ltd., Poland. Other chemicals were supplied
by commercial firms operating in Poland.
Animals
Male Wistar Krf: (WI) WU rats (12-14 weeks
old) obtained from the Jagiellonian University
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Faculty of Pharmacy Breeding Laboratory (KrakÛw,
Poland) were maintained on standard diet
(Murigran, Poland) and water ad libitum, and
allowed a minimum 7 days acclimatization to appro-
priate facilities (12 h dark/light period, 20-23OC
ambient temperature, and 40-60% relative humidity)
prior to inclusion in the present experiment. In this
experiment the Polish law on the protection of ani-
mals was followed (16). 
Experimental design
BE, PY, and MP solutions were prepared
immediately before dosing by mixing these chemi-
cals with 0.9% saline to obtain a dose volume of 2
mL/kg body weight (b.w.), and were administered to
rats by subcutaneous (BE) and intraperitoneal (PY
and MP) injection, respectively. Rats were random-
ly assigned to groups of 5 animals each. Rats in one
group were treated with BE alone at a single dose of
1.25 mmol/kg b.w. The animals in other groups,
beside the same dose of BE, received PY or MP at a
single dose of 0.045, 0.09, 0.18 or 0.36 mmol/kg
b.w. These antidotes were injected simultaneously,
2 h or 5 h after BE administration. Control animals
received 2.0 ml of 0.9% saline and served as vehicle
control.
Hematologic analysis
At the end of the required period after BE
administration, i.e. 0, 3, 6, 24, and 48 h, blood sam-
ples from end tail vein of rats were collected into
heparinized test-tubes. Blood samples were ana-
lyzed by means of hematologic analyzer Cobas
Micros ROCHE. The following indices were meas-
ured: red blood cells (RBCs) and reticulocyte
counts, packed cell volume (PCV), mean cell vol-
ume (MCV), total hemoglobin concentration
(HGB), plasma hemoglobin concentration (HGBp),
mean cell hemoglobin (MCH), and mean cell hemo-
globin concentration (MCHC). Hematologic analy-
ses were systematically checked by means of stan-
dard human blood CBC-3D Hematology Control (R
& D System Inc., Minneapolis, USA). A day-to-day
precision of measurement of RBC, PCV, and HGB
in blood was 4.2%, 4.5%, and 7.2% (n = 30), respec-
tively. 
Statistical analysis
All results are expressed as mean ± S.D. of val-
ues obtained in five individual rats. The results were
statistically evaluated by means of one-way
ANOVA followed by Tukeyís test or by unpaired t-
test as appropriate after assessment of a normal dis-
tribution of variables by means of Shapiro-Wilkís W
tests. The regression equations and correlation coef-
ficients were calculated with the STATISTICA ñ
version 6.0 computer program. 
RESULTS
Subcutaneous injection of BE to rats at a single
dose of 1.25 mmol/kg b.w. caused distinct intravas-
cular hemolysis expressed by the reduction in the
RBC count, decrease in the HGB concentration and
increase in the free HGB in plasma and rise in the
reticulocyte numbers in peripheral blood. All hema-
tologic parameters demonstrated time dependence.
Both RBC count and HGB concentration gradually
decreased, whereas reticulocyte numbers increased
with time after dosing. The maximum value of free
HGB in plasma occurred at 6 h after BE administra-
tion (Figure 1). RBC count and HGB concentration
correlated well with time of the experiment.
Both PY and MP administered simultaneously
with BE protected rats against appearance of
hemolytic anemia sings. PY at the doses of 0.09,
0.18, and 0.36 mmol/kg b.w. completely abolished
the hemolytic effect of BE, whereas at the lowest
dose (0.045 mmol/kg b.w.) only partially exerted
protective effect (Figure 1). 
MP at each dose level (0.045-0.36 mmol/kg
b.w.), injected to rats simultaneously with BE, acted
against hematotoxicity of BE (Figure 2). Both PY
and MP at highest dose level (0.36 mmol/kg b.w.),
given 2 or 5 h after BE administration, did not pro-
tect rats against hemolytic anemia signs (Figure 3
and 4). The lack of protection effect of PY and 4-MP
in these rats was also expressed by the negative cor-
relation between RBC count or HGB concentration
and time of the experiment (Table 1).
DISCUSSION
BE is readily absorbed from skin, and both res-
piratory and gastrointestinal tracts. This chemical is
metabolized in rats by three pathways in the liver,
skin, and testes (14, 16, 17). The major metabolic
pathway is via ADH and ALDH to the primary
metabolite butoxyacetic acid (BAA) (14, 17, 19).
BAA is then excreted in the urine (8, 14). This
metabolite is believed to be responsible for the
hematotoxic manifestations of BE poisoning. The
other two pathways involve BE conjugation with
glucuronic acid and sulfate. These two pathways are
believed to be primary detoxifying metabolism of
the parent compound (14). The fraction of BE con-
verted to the glucuronide and sulfate conjugates has
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Figure 1. Time-course (for 48 h) of the effects of BE alone at the dose level of 1.25 mmol/kg b.w. and its combination with PY at the dose
levels of 0.045-0.36 mmol/kg b.w. on RBC, HGB, HGBp, and reticulocyte counts after simultaneous administration. *The values signifi-
cantly different from control group.
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Figure 2. Time-course (for 48 h) of the effects of BE alone at the dose level of 1.25 mmol/kg b.w. and its combination with MP at the dose
levels of 0.045-0.36 mmol/kg b.w. on RBC, HGB, HGBp, and reticulocyte counts after simultaneous administration. *The values signifi-
cantly different from control group.
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Figure 3. Time-course (for 48 h) of the hematologic effects of BE (1.25 mmol/kg b.w.) alone and its combination with PY (0.36 mmol/kg
b.w.) administered 2 or 5 h later. *The values significantly different from control group.
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Figure 4. Time-course (for 48 h) of the hematologic effects of BE (1.25 mmol/kg b.w.) alone and its combination with MP (0.36 mmol/kg
b.w.) administered 2 or 5 h later. *The values significantly different from control group. 
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been shown to increase significantly after inhibition
of BE metabolism to BAA by PY or ethanol (14).
The occurrence of intravascular hemolysis in ani-
mal models of BE poisoning has been well evidenced.
In vivo and in vitro studies have ascribed a potent
hemolytic activity to BAA but not to BE (20, 21).
Hemolytic activity of BAA leads to a decrease in the
number of circulating RBC and HGB concentration,
and an increase in the concentration of free hemoglo-
bin in plasma of peripheral blood. Subsequently, retic-
ulocyte counts considerably increase as a result of
regenerative process (8, 14, 15). Although human ery-
throcytes are resistant to the hemolytic action of BAA,
even at concentrations several times higher than those
producing hemolysis in rats (20, 22), some reports
described a decline in number of RBC, hemoglobin
concentration in blood and hematuria in humans fol-
lowing suicidal ingestion of BE or occupational expo-
sure to this chemical (9, 23-25).
Treatment of BE poisoning have been based on
the hypothesis that block of the metabolic activation
of this compound prevents organism against its toxic
effects. Data in the available literature indicate that
inhibition of ADH and ALDH with PY and
cyanamide (ALDH-inhibitor), respectively, prevent-
ed animals treated with BE at toxic doses against
hematotoxicity (14, 15). Other animal studies have
shown that ethanol therapy may prevent BE-induced
hemolysis by competitive inhibition of its metabo-
lism (15, 26). These data confirm the role of meta-
bolic activation in BE hematotoxicity.
The results obtained in the present study indi-
cate that both PY and MP exert distinct protective
effect in rats subcutaneously treated with BE. These
antidotes administered simultaneously with BE pro-
tected animals against onset of hemolytic anemia
sings. This protection effect was dose-dependent.
PY at doses of 0.09, 0.18 and 0.36 mmol/kg b.w.,
similarly as the MP at each dose level (0.045-0.36
mmol/kg b.w.), completely abolished the hemolytic
action of BE. PY at the lowest dose (0.045 mmol/kg
b.w.) only partially exerted protection effect in the
rats treated with single dose of BE. Both PY and MP
injected intraperitoneally 2 or 5 h after BE adminis-
tration did not protect rats against onset signs of
hemolytic anemia. The correlations between RBC
counts or HGB concentration and time of the exper-
iment confirmed the lack of a protective effect of
these antidotes in rats intoxicated with BE. The rea-
son for the lack of efficiency of these antidotes is
mainly toxicokinetics of BE. BE is rapidly metabo-
lized to BAA with its maximal levels in peripheral
blood at 10-30 min after intraperitoneal or intra-
venous BE administration (27, 28). 
The data obtained in the present study suggest
that PY and MP may decrease the metabolic conse-
quences of BE poisoning and may be of therapeutic
value when administered early during the course of
the intoxication before hemolysis have occurred.
This suggestion is consistent with literature data
which indicate that MP is a potent competitive
inhibitor of ADH, especially ADH1 and ADH2 in
rat liver and ADH1, ADH3 and ADH4 in rat skin
(17). Additionally, MP in combination with
hemodialysis or without hemodialysis is safe and
effective in treatment of confirmed ethylene glycol
or methanol poisoning (29, 30). During ethanol
intoxication, in humans given MP a 30-40%
decrease in the ethanol elimination rate was
observed (31). It was found that the inhibition of
ethanol metabolism by pretreatment with MP may
lead to prolongation of its neurobehavioral toxicity
in mice (32).
In conclusion, it is clear that BE is a strong
hemolytic agent after metabolic activation by ADH
and ALDH. Both PY and MP, as selective inhibitors
of ADH, may decrease the hemolytic effect of BE
and may be of therapeutic value when administered
early during the course of intoxication by this chem-
ical. 
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Erratum to Acta Pol. Pharm. Drug Res. Vol. 63, No. 5:
in the pages ìContentsî (327-328) the following corrections should be made:
p. 391 authorís name should be Eløbieta L. Anuszewska
p. 452 in the title should be: bortezomib (VelcadeÆ)
addition: p. 465. Monika GrudzieÒ, Franciszek PluciÒski, Aleksander P. Mazurek 
Molecular properties of econazole and sulconazole relevant to bioavailability. (the title and authors
names should be also added in the Index for vol. 63, 2006)
